Company will leverage the IP in metabolic diseases and cancer.
Elixir Pharmaceuticals gained an exclusive license to Boston University’s intellectual property covering the use of modulators of SIRT1, a member of the sirtuin class of protein deacetylase enzymes.
SIRT is a class of seven naturally occurring human enzymes, known to affect the storage and use of energy in cells. SIRT1 is the human equivalent of Sir2, a gene identified in yeast that has been recognized to play a key role in the control of lifespan, metabolism, resistance to stress, and other cellular regulatory pathways.
The arrangement with Boston University encompasses therapeutic applications for SIRT1 modulators in metabolic diseases and modulation of SIRT1 for antiangiogenic activity to treat cancer.
